Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial

In the APeX-2 trial (n=121), berotralstat was associated with a reduction in the rate of investigator-confirmed hereditary angioedema attacks versus placebo (2.35 attacks/month) at both 110mg (1.65 attacks/month; p=0.024) and 150mg (1.31 attacks/month; p<0.001) doses.

Source:

European Journal of Allergy and Clinical Immunology